HK1082180A1 - Administration of dendritic cells partially matured in vitro for the treatment of tumors - Google Patents

Administration of dendritic cells partially matured in vitro for the treatment of tumors

Info

Publication number
HK1082180A1
HK1082180A1 HK06101427.5A HK06101427A HK1082180A1 HK 1082180 A1 HK1082180 A1 HK 1082180A1 HK 06101427 A HK06101427 A HK 06101427A HK 1082180 A1 HK1082180 A1 HK 1082180A1
Authority
HK
Hong Kong
Prior art keywords
dendritic cells
tumor
cells
partially matured
administration
Prior art date
Application number
HK06101427.5A
Other languages
English (en)
Inventor
Marnix L Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of HK1082180A1 publication Critical patent/HK1082180A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK06101427.5A 2002-12-06 2006-02-02 Administration of dendritic cells partially matured in vitro for the treatment of tumors HK1082180A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
PCT/US2003/038672 WO2004053072A2 (en) 2002-12-06 2003-12-05 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Publications (1)

Publication Number Publication Date
HK1082180A1 true HK1082180A1 (en) 2006-06-02

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101427.5A HK1082180A1 (en) 2002-12-06 2006-02-02 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Country Status (19)

Country Link
US (2) US20060057120A1 (pt)
EP (2) EP1567155B1 (pt)
JP (2) JP4859169B2 (pt)
KR (1) KR101144196B1 (pt)
CN (2) CN102600461B (pt)
AT (1) ATE486125T1 (pt)
AU (2) AU2003293411B2 (pt)
BR (1) BRPI0317064B8 (pt)
CA (1) CA2509058A1 (pt)
DE (1) DE60334725D1 (pt)
DK (1) DK1567155T3 (pt)
ES (1) ES2354944T3 (pt)
HK (1) HK1082180A1 (pt)
IL (1) IL169002A (pt)
MX (1) MXPA05006042A (pt)
PL (1) PL377209A1 (pt)
PT (1) PT1567155E (pt)
RU (1) RU2348418C2 (pt)
WO (1) WO2004053072A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144196B1 (ko) * 2002-12-06 2012-05-21 노쓰웨스트 바이오써라퓨틱스, 인크. 종양 치료를 위한 시험관내 부분 성숙된 수지상 세포를 포함하는 조성물
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (fr) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Cellules dendritiques matures chargees d'un polylysat de tumeurs, et vaccin antitumoral a base desdites cellules
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
SG192449A1 (en) * 2008-03-27 2013-08-30 Geron Corp Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
SG177582A1 (en) * 2009-07-09 2012-03-29 Cellerix Sa Methods and compositions for use in cellular therapies
BR112012019267B1 (pt) * 2010-02-10 2022-03-03 Immunicum Ab Composição englobando célula dendrítica (dc) madura próinflamatória, e uso da dita célula
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
GB2534478A (en) * 2012-06-27 2016-07-27 Hasumi Int Res Found Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
US20150202291A1 (en) 2013-11-05 2015-07-23 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CA2990640A1 (en) * 2015-06-30 2017-01-05 Northwest Biotherapeutics, Inc. Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
RU2749610C2 (ru) 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2215991T3 (es) 1992-04-01 2004-10-16 The Rockefeller University Procedimiento para la proliferacion (in vitro) de precursores de celulas dendriticas y su uso para producir inmunogenos.
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CN1330557A (zh) * 1998-09-15 2002-01-09 匹兹堡大学联邦系统高等教育 原位注射具有基因上增进细胞因子表达的抗原呈递细胞
WO2000020563A1 (fr) * 1998-10-02 2000-04-13 Mitsubishi Chemical Corporation Procede d'induction d'une immunite cellulaire et cellules possedant cette immunite
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
BR0009772A (pt) * 1999-04-14 2002-01-08 Us Health Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (en) 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
JP2005505270A (ja) * 2001-09-06 2005-02-24 ノースウエスト バイオセラピューティクス，インコーポレイティド 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法
KR101144196B1 (ko) * 2002-12-06 2012-05-21 노쓰웨스트 바이오써라퓨틱스, 인크. 종양 치료를 위한 시험관내 부분 성숙된 수지상 세포를 포함하는 조성물
DK1604016T3 (da) * 2003-02-27 2009-05-18 Northwest Biotherapeutics Inc In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler

Also Published As

Publication number Publication date
RU2348418C2 (ru) 2009-03-10
BRPI0317064B8 (pt) 2021-05-25
KR20050084189A (ko) 2005-08-26
AU2003293411B2 (en) 2010-10-28
RU2005121256A (ru) 2006-02-10
US20060057120A1 (en) 2006-03-16
JP5707284B2 (ja) 2015-04-30
ATE486125T1 (de) 2010-11-15
PT1567155E (pt) 2011-01-28
MXPA05006042A (es) 2005-09-21
KR101144196B1 (ko) 2012-05-21
WO2004053072A3 (en) 2005-06-16
PL377209A1 (pl) 2006-01-23
JP4859169B2 (ja) 2012-01-25
AU2011200352B2 (en) 2013-06-27
US20120251561A1 (en) 2012-10-04
EP1567155B1 (en) 2010-10-27
BR0317064A (pt) 2005-10-25
EP2260861A1 (en) 2010-12-15
EP1567155A2 (en) 2005-08-31
JP2006510667A (ja) 2006-03-30
DE60334725D1 (de) 2010-12-09
JP2011246493A (ja) 2011-12-08
BRPI0317064B1 (pt) 2020-11-03
CN1738619B (zh) 2012-04-18
EP1567155A4 (en) 2006-12-13
CN102600461B (zh) 2017-07-14
IL169002A (en) 2015-01-29
WO2004053072A2 (en) 2004-06-24
DK1567155T3 (da) 2011-02-14
CN1738619A (zh) 2006-02-22
ES2354944T3 (es) 2011-03-21
AU2011200352A1 (en) 2011-02-17
CA2509058A1 (en) 2004-06-24
AU2003293411A1 (en) 2004-06-30
CN102600461A (zh) 2012-07-25

Similar Documents

Publication Publication Date Title
HK1082180A1 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
Libraty et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.
Bilsborough et al. Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties
Grabbe et al. Tumor antigen presentation by epidermal antigen‐presenting cells in the mouse: modulation by granulocyte‐macrophage colony‐stimulating factor, tumor necrosis factor α, and ultraviolet radiation
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
Salio et al. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
Handel-Fernandez et al. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice.
ES2113980T3 (es) Ligandos solubles para cd40.
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
Waltenbaugh et al. Alcohol consumption alters antigen‐specific Th1 responses: mechanisms of deficit and repair
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
WO2002036141A3 (en) Method of enhancing lymphocyte-mediated immune responses
Mazzoccoli et al. Immune system alterations in lung cancer patients
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
Holzer et al. Haptens as drugs: contact allergens are powerful topical immunomodulators
MXPA04001872A (es) Modelo de exposicion a micoplasma bovis, procedimiento para administrar m. bovis y procedimientos para inducir lesiones pulmonares neumonicas.
MX2023001622A (es) Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
Gelfand Essential role of T lymphocytes in the development of allergen-driven airway hyperresponsiveness
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
Son et al. Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti‐tumor effects when combined with interleukin‐2
Enioutina et al. The induction of systemic and mucosal immunity to protein vaccines delivered through skin sites exposed to UVB
Harada et al. Role of the endogenous production of interleukin 12 in immunotherapy
WO2002015915A3 (en) Method for inducing an anti-tumor and anti-cachexia immune response in mammals
Iwashita et al. Potent stimuli combined with lipopolysaccaride and IFNγ may improve immunotherapy against HCC by increasing the maturation and subsequent immune response of the dendritic cells

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211207